We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
Studio Pictures Ltd is a UK-based film and TV production company founded by producers Adam Rolston and David Braithwaite in 2019. Specializing in creating high-quality British entertainment content, the company focuses on adapting books to screen and telling unique true-life stories that entertain and inspire both domestic and international audiences. With successful productions like "A Street Cat Named Bob," the company is building a strong brand and reputation in the industry. Studio Pictures has access to top creative talent and collaborates with major studios like Warner Bros, Sony Pictures, Lionsgate, and Studio Canal. The company is located at Twickenham Studios in Richmond, UK.
days to go: 11 investment: Withheld
Celestial Labs is a drone display company that combines advanced technology with organic performance. The company's proprietary 'Skytheatre' display is a dynamic, safe and green alternative to carbon-intensive fireworks and represents a new frontier for the live event industry. Composed of a creative collective of award-winning filmmakers, musicians, developers, entrepreneurs, and storytellers, the company is constantly pushing the boundaries of drone display innovation, where technology meets imagination. The Human Support division of Celestial is a not-for-profit initiative that aims to lift the spirits of those who witness Celestial's displays whilst imparting crucial information. The company aims to enlist the support and guidance of city leadership partners, industrial conglomerates, and seek grant funding.
days to go: Stretch investment: Withheld
Postio is a secure, dynamic, community driven delivery system. Postio offer the option of same-day and within-the-hour delivery to all. Sending and receiving parties are able to track their driver and therefore their package in realtime.  
days to go: Expired investment: £35,220
Player+ is an introduction gateway to exclusive video content tailored to your preferences. With over 200 million Amazon households worldwide connected through genre-specific TV Apps, Player+ offers premium content curated just for you, accessible on leading smart TVs, devices, cable, and satellite platforms. Enjoy the convenience of all your favorite genre-based content in one app, including top news channels in NewsPlayer+ and a Performing Arts hub in StagePlayer+. Exciting expansions into new categories are currently in progress.
days to go: Expired investment: £249,114
Book My Garage has been launched to help the independent garage market in winning the online race by giving them all the tools to keep their business profitable, win new customers and to keep their diary full.
days to go: Expired investment: £668,189
gowithYamo aims to make art more accessible to everyone, from art newbies to experienced gallery-goers through its application. Users can collect Yamo points by checking-in to galleries and exchanging them for rewards such as art prints and exhibition tickets from the company's in-app store. gowithYamo provides support to galleries, museums and artists by exposing them to an active community of art lovers. The company also offers custom-built virtual exhibition spaces where artists can show and sell their work to a sizeable digital audience. gowithYamo has collaborated with art entities like Roy's Art Fair, The Other Art Fair, Harlesden High Street, and many others. It has a social media presence of 50,000+ followers. The company will use 30% of the investment to expand across different demographics, 25% to further finetune its virtual exhibition platform, 20% for marketing, and 25% to implement Artificial Intelligence (AI) in the gowithYamo app to help recommend exhibitions to its users.

Pitch Rated

52%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £161,105
Over the past 8 years, Advatech Healthcare has created Hippo, a proven disabled and non-emergency patients transportation services (NEPTS) in the Essex area. Due to its dependability and efficiency, Hippo is now poised to become the UK's best national wheelchair accessible healthcare services on a wearable technology platform. According to the Office for Technology Statistics data, there are 13.37 million people disabled in the UK who lack dedicated non-emergency transportation. Hippo could save the National Health Service (NHS) up to 60% on transportation costs increasing faster hospital bed rotation and providing dedicated transportation for disabled and non-emergency patients with a medically trained staff. It also offers medical and technological necessities not offered by many leading operators. Currently, the company operates within the Essex area. By the end of 2020, the company aims to commence seven new contracts it has signed with the NHS. It also signed a deal with Cambridge Adult Social Care that is expected to close, within a 5-year term and generate over £200,000 per year.

Pitch Rated

81%

Gold

rating powered by

CROWD RATING™

days to go: Expired investment: Withheld
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph